EXODUS-enabled High-throughput Multi-omics Profiling of Extracellular Vesicles for Diagnosis of Preclinical Alzheimer's Disease

EXODUS 支持的细胞外囊泡高通量多组学分析用于临床前阿尔茨海默病的诊断

• 批准号: 10604194
• 负责人: Yuchao Chen
• 金额: $ 11.04万
• 依托单位: WELLSIM BIOMEDICAL TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-30 至 2023-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10604194
• 关键词: Address; Aliquot; Alzheimer disease detection; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer' s disease patient; Alzheimer' s disease therapy; Alzheimer’s disease biomarker; Bioinformatics; Biological Assay; Biological Markers; Biomedical Technology; Blood; Blood - brain barrier anatomy; Blood Circulation; Brain Injuries; CLIA certified; Cerebrospinal Fluid; Clinical; Communities; Data; Devices; Diagnosis; Diagnostic tests; Early Diagnosis; Face; Goals; Intervention; Label; Laboratories; Malignant neoplasm of urinary bladder; Mediator of activation protein; Methodology; Molecular; Neurodegenerative Disorders; Neurons; Outcome; Pathogenesis; Pathologic; Patients; Performance; Peripheral; Phase; Plasma; Proteomics; Psyche structure; Reproducibility; Research; Research Personnel; Running; Sampling; Small Business Innovation Research Grant; Source; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Speed; Techniques; Technology; Time; Ultrafiltration; Validation; Variant; acute pancreatitis; aging population; base; biomarker discovery; biomarker panel; design; extracellular vesicles; flexibility; global health; improved; innovation; lipidomics; liquid biopsy; methylomics; multiple omics; novel; novel marker; novel strategies; phase 1 study; pre-clinical; predictive modeling; symptom treatment; targeted treatment; technological innovation; testing services; transcriptomics

PROJECT SUMMARY / ABSTRACT Alzheimer's disease (AD) is the most widespread neurodegenerative disorder and has caused a major global health concern with the aging population. Early diagnosis of AD before irreversible brain damage or mental decline is critical for timely intervention, symptomatic treatment, and improved patient function. Accumulating studies indicate that neuron-derived extracellular vesicles (EVs) are important biomarkers for AD. However, researchers face significant challenges in the efficient isolation and accurate analysis of EVs, limiting the broad study and application of EVs in early diagnosis or targeted therapy of AD. WellSIM proposes to develop and validate a high-throughput platform and workflow based on our revolutionary EXODUS technique for reliable and reproducible isolation and analysis of EVs from plasma and CSF with unparalleled throughput, purity, yield, and sensitivity. Based on hi-EXODUS-NGS and hi-EXODUS-MS integrative analysis, transcriptomic and proteomic profiling of EVs will be developed to discover and detect EV-derived multi-class biomarkers for AD diagnosis.

项目摘要 /摘要 阿尔茨海默氏病（AD）是最广泛的神经退行性疾病，已引起主要的全球性 对人口老龄化的健康关注。在不可逆转的脑损伤或精神上早期诊断AD的早期诊断 下降对于及时干预，症状治疗和改善患者功能至关重要。累积 研究表明，神经元衍生的细胞外囊泡（EV）是AD的重要生物标志物。然而， 研究人员在对电动汽车的有效隔离和准确分析方面面临重大挑战，限制了广泛的 电动汽车在早期诊断或AD的靶向治疗中的研究和应用。威尔斯姆建议开发和 根据我们的革命性出埃及记验证高通量平台和工作流程 从血浆和CSF的EV可再现的分离和分析，并具有无与伦比的吞吐量，纯度，产量和 灵敏度。基于Hi-exodus-NG和Hi-exodus-MS集成分析，转录组和蛋白质组学 将开发电动汽车的分析，以发现和检测EV衍生的多级生物标志物进行AD诊断。